AstraZeneca plc (LON:AZN) Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage..

AstraZeneca plc (LON:AZN) Tagrisso (osimertinib) has been approved in China for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung..

AstraZeneca plc (LON:AZN) and Saint Luke’s Mid America Heart Institute today announced high-level results of the primary analysis from the DARE-19 Phase III trial assessing the potential of Farxiga (dapagliflozin)..

AstraZeneca PLC (LON:AZN) AZD1222 US Phase III primary analysis confirms safety and efficacy. Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US..

AstraZeneca plc (LON:AZN) US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. This..

AstraZeneca plc (LON:AZN) updates on KESTREL Phase III trial of Imfinzi with or without tremelimumab in the 1st-line treatment of recurrent or metastatic head and neck cancer. The KESTREL Phase..

AstraZeneca plc (LON:AZN) Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure (NYHA class II-IV)..

AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of..

AstraZeneca’s Symbicort Turbuhaler (budesonide/formoterol 160/4.5mcg) has been approved in China as an anti-inflammatory reliever to be taken as-needed in response to symptoms to achieve asthma control in patients with mild asthma aged..

AstraZeneca plc (LON:AZN) and Daiichi Sankyo Company, Limited’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric..

AstraZeneca plc (LON:AZN) Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced,..

AstraZeneca plc (LON:AZN) Farxiga (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney disease (CKD) in adults with and without type-2..

AstraZeneca plc (LON:AZN) has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to..

AstraZeneca plc (LON:AZN) COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New..

AstraZeneca plc (LON:AZN) and MSD’s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers. The three approvals authorise Lynparza for: maintenance treatment after 1st-line..

AstraZeneca plc (LON:AZN)’s Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC)..

AstraZeneca plc (LON:AZN) Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union for an additional dosing option, 1,500mg fixed dose every four weeks, in the approved indication..